Compare DCI Indonesia Tbk (DCII) vs Kimia Farma Tbk (KAEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DCI Indonesia Tbk vs Kimia Farma Tbk — how do they compare? DCI Indonesia Tbk trades at Rp198,675 (market cap 473.59T), while Kimia Farma Tbk trades at Rp454 (market cap 2.53T). The key difference: DCI Indonesia Tbk is far larger — about 187.2× Kimia Farma Tbk's market cap. Which is the better fit depends on your goals.
| DCII | KAEF | |
|---|---|---|
Market Cap | 473.59T | 2.53T |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DCI Indonesia Tbk
PT DCI Indonesia Tbk (the Company) was established in Indonesia based on Notarial Deed No. 143 of Buntario Tigris, S.H., S.E., M.H., on July 18, 2011. The Company started its commercial operations in 2013. The Company parent entity and ultimate controlling party is DCI International Holding Pte. Ltd., Singapore.
Read more on DCII →About Kimia Farma Tbk
PT Kimia Farma Tbk (the Company) was established based on the Notarial Deed No. 18 dated August 16, 1971, as amended by Notarial Deed No. 18 dated October 11, 1971 of Soelaeman Ardjasasmita, S.H., under its original name Perusahaaan Negara Farmasi dan Alat Kesehatan Bhinneka Kimia Farma (PN Farmasi Kimia Farma). PN Farmasi Kimia Farma consist of : Badan Pimpinan Umum Perusahaan-perusahaan Negara Farmasi dan Alat Kesehatan (established 1961) Perusahaan Negara Farmasi Alat Kesehatan Radja Farma (established 1961) Perusahaan Negara Farmasi Alat Kesehatan Nakula Farma (established 1961) Perusahaan Negara Farmasi Alat Kesehatan Bhinneka Kimia Farma (established 1961)PN Farmasi Kimia Farma has been changed to PT Kimia Farma (Persero) Tbk based on notarial deed dated October 11, 1971. The company’s article of association has been amended from time to time, the latest of which was covered by notarial deed dated Sept 22, 2000 by Wahjono H, SH concerning Right Issue (as public company). The Company operates 210 apoteks, 6 units production and 40 branches pharmacy wholesale. The company’s share will be listed in BEJ and BES.
Read more on KAEF →
